Results 201 to 210 of about 20,124 (257)

Progress of Immunotherapies in Parkinson's Disease

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
Parkinson's disease (PD) is caused by an immune disorder triggered by α‐synuclein, leading to a persistent neuroinflammatory cycle that drives the disease from non‐motor symptoms to the motor stage. Second, it presents active and passive immunotherapy strategies targeting α‐synuclein and their potential in slowing down the disease progression.
Yong Peng   +10 more
wiley   +1 more source

Opening new frontiers with catalytic nucleic acids in miRNA inhibition. [PDF]

open access: yesFront Pharmacol
Patutina O   +3 more
europepmc   +1 more source

Rapid, Single-Step Monitoring of Monoclonal Antibody Bioavailability by Using a TNF-α-Based Multiepitope DNA Nanoswitch. [PDF]

open access: yesAnal Chem
Di Lena D   +9 more
europepmc   +1 more source

Following the central dogma: Nanopore sequencing from DNA and RNA to proteins. [PDF]

open access: yesiScience
Wang Y   +7 more
europepmc   +1 more source

Intradermal delivery of lipophilic siRNAs enables prolonged skin retention and sustained gene silencing in a porcine model. [PDF]

open access: yesNat Commun
Fakih HH   +21 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy